BRIEF published on 04/29/2026 at 13:44, 18 days 1 hour ago Croissance impressionnante des ventes de UZEDY® au T1 2026 Schizophrénie Medincell Teva Pharmaceuticals UZEDY® Ventes T1 2026
BRIEF published on 04/29/2026 at 13:44, 18 days 1 hour ago UZEDY® Q1 2026 Sales Surge by 62% FDA Approvals Olanzapine LAI UZEDY® Sales Teva Partnership Medincell Growth
BRIEF published on 04/29/2026 at 13:44, 18 days 1 hour ago Les ventes d'UZEDY® au premier trimestre 2026 devraient bondir de 62 %. Olanzapine LAI Ventes UZEDY® Partenariat Avec Teva Approbations De La FDA Croissance De Medincell
BRIEF published on 04/29/2026 at 13:44, 18 days 1 hour ago Impressive sales growth for UZEDY® in Q1 2026 Schizophrenia Medincell Teva Pharmaceuticals UZEDY® Q1 2026 Sales
PRESS RELEASE published on 04/29/2026 at 13:39, 18 days 1 hour ago Inside Information / Other news releases Medincell's partner Teva Pharmaceuticals reports UZEDY Q1 2026 net sales of $63M, a 62% increase year-on-year. Olanzapine LAI NDA accepted by FDA. Medincell focuses on long-acting injectable treatments across various therapeutic areas Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY Long-acting Injectable
PRESS RELEASE published on 04/29/2026 at 13:39, 18 days 1 hour ago Informations privilégiées / Autres communiqués Medincell annonce une forte croissance des ventes de UZEDY aux Etats-Unis, une formulation injectable approuvée par la FDA pour la schizophrénie et le trouble bipolaire. De nouvelles avancées pour l'olanzapine LAI sont également en cours FDA Schizophrénie Medincell Teva UZEDY
BRIEF published on 04/20/2026 at 11:18, 27 days 4 hours ago Franchissement de seuil par BNP Paribas Développement chez MEDINCELL Euronext Paris Droits De Vote Franchissement De Seuil BNP Paribas Medincell
BRIEF published on 04/20/2026 at 11:18, 27 days 4 hours ago BNP Paribas Développement crosses a threshold at MEDICELL Euronext Paris Voting Rights BNP Paribas Threshold Crossing MEDICELL
PRESS RELEASE published on 04/20/2026 at 11:13, 27 days 4 hours ago Franchissement de seuil Déclaration de franchissement de seuil par BNP Paribas Développement concernant MEDINCELL sur Euronext Paris Euronext Paris Droits De Vote Franchissement De Seuil Medincell BNP Paribas Développement
BRIEF published on 04/02/2026 at 19:05, 1 month 14 days ago Medincell: Update on capital and voting rights Share Capital Voting Rights Shares Euronext AMF
Published on 05/16/2026 at 01:15, 1 day 14 hours ago Findev Inc. Announces a New Member of the Board of Directors
Published on 05/16/2026 at 00:00, 1 day 15 hours ago Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate
Published on 05/15/2026 at 23:10, 1 day 16 hours ago Golden Minerals Reports First Quarter 2026 Financial Results
Published on 05/16/2026 at 16:08, 23 hours 30 minutes ago The publication of the audited financial statements for 2025 will be postponed to 12 June 2026 – management does not expect any significant changes to the figures already published
Published on 05/15/2026 at 20:10, 1 day 19 hours ago CPIPG Communication Concerning Voluntary Offer on NEXT RE Shares – Provisional Results Announcement
Published on 05/15/2026 at 18:10, 1 day 21 hours ago Virtual Science AI launches first AI-driven competitor activity tracking platform to support pharma asset launch success
Published on 05/15/2026 at 15:08, 2 days ago Notice of exercise of early redemption option of the subordinated note ISIN : FR0010203026
Published on 05/15/2026 at 15:00, 2 days ago Exercice de l’option de remboursement de l'instrument subordonné FR0010203026
Published on 05/15/2026 at 10:09, 2 days 5 hours ago Groupe Crit : Modalités de mise à disposition des documents préparatoires à l’Assemblée Générale Mixte du 05 juin 2026.
Published on 05/14/2026 at 09:03, 3 days 6 hours ago Coup d'envoi pour les carrières dans l'esport : 65% de la population mondiale réclame plus de formations et de parcours professionnels pour le jeu vidéo de compétition
Published on 05/13/2026 at 18:02, 3 days 21 hours ago ALTAREA : Assemblée Générale Mixte du 4 juin 2026 MODALITES DE MISE A DISPOSITION DES DOCUMENTS PREPARATOIRES
